RANDOMIZED STUDY OF 5 FLUOROURACIL AND CISPLATIN AS NEOADJUVANT THERAPY IN HEAD AND NECK-CANCER - A PRELIMINARY-REPORT

被引:50
作者
MARTIN, M
HAZAN, A
VERGNES, L
PEYTRAL, C
MAZERON, JJ
SENECHAUT, JP
LELIEVRE, G
PEYNEGRE, R
机构
[1] CTR HOSP MONTFERMEIL,MONTFERMEIL,FRANCE
[2] CTR HOSP INTERCOMMUNAL CRETEIL,DEPT CANCEROL,F-94010 CRETEIL,FRANCE
[3] CTR HOSP INTERCOMMUNAL CRETEIL,SERV ORL,F-94010 CRETEIL,FRANCE
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1990年 / 19卷 / 04期
关键词
Head and Neck cancer; Neoadjuvant chemotherapy;
D O I
10.1016/0360-3016(90)90021-B
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A randomized prospective study of 5 fluorouracil (5-FU) and Cis platin preceeding definitive local treatment for squamous cell carcinoma of the head and neck region was initiated in September 1986. Seventy-five patients were stratified by site (oral cavity-12, oropharynx-28, larynx-16, hypopharynx-19), and by Stage (Stage II-20, Stage III-43, Stage IV-12) and randomized to receive definitive local treatment (surgery and post-operative radiation or radiation alone) or chemotherapy followed by definitive local treatment. Chemotherapy consisted of three cycles of 120 hr 5-FU infusion 1 g/m2/day plus Cis platin 100 mg/m2 on day 1 on each cycle. Response to chemotherapy was complete in 17 patients (46%) for an overall response rate of 68%. All the patients have completed therapy with a median follow-up of more than 12 months. After local treatment, the complete response rate is 84% for the control group and 86% in the chemotherapy group. Acturial disease-free survival at 1 year is 61% in the control group and 73% in the chemotherapy group (p = 0.25). These preliminary results show that in spite of initial tumor response, neoadjuvant chemotherapy does not improve long-term control and survival. © 1990.
引用
收藏
页码:973 / 975
页数:3
相关论文
共 11 条
[1]  
CARTER SK, 1977, SEMIN ONCOL, V4, P413
[2]  
DECKER DA, 1983, CANCER, V51, P1353, DOI 10.1002/1097-0142(19830415)51:8<1353::AID-CNCR2820510805>3.0.CO
[3]  
2-I
[4]  
HASS C, 1986, P AM ASSOC CANC RES, V27, P185
[5]  
HOLOYE PY, 1983, NEW ENGL J MED, V308, P75
[6]  
KAPLAN E, 1958, J AM STAT ASSOC, V58, P475
[7]  
MARTIN M, 1986, P AM SOC CLIN ONCOL, V141
[8]  
SCHULLER DE, 1984, P INT C HEAD NECK CA, P48
[9]   INTEGRATION OF CHEMOTHERAPY INTO THE COMBINED MODALITY THERAPY OF HEAD AND NECK SQUAMOUS CANCER [J].
TAYLOR, SG .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1987, 13 (05) :779-783
[10]  
WITTES R, 1979, CANCER TREAT REP, V63, P1533